Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

NCT06664021 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Tislelizumab combined with S-1

Sponsor

Anhui Provincial Hospital